Search results for "Chronic Myeloproliferative Neoplasm"

showing 3 items of 3 documents

A case of severe dermatitis in a patient with Polycythemia Vera during cytoreductive therapy

2019

Polycythemia Vera (PV) is a Philadelphia-negative chronic myeloproliferative neoplasm (MPN) mainly characterized by erythrocytosis. In this report we describe a case of severe cutaneous toxicity in patients with PV treated with hydroxyurea. A 72-year-old woman diagnosed with PV with V617F mutation of JAK2 performed more than 10 years before and treated with hydroxyurea plus phlebotomies and low-dose ASA for about 7 years addressed our center for the appearance of serious dermatitis at the face symptomatic for severe itch. The patient underwent a dermatology visit with diagnosis of desquamative dermatitis due to iatrogenic cause related to the use of hydroxyurea. HU was stopped for a month w…

Adverse eventmedicine.medical_specialtybusiness.industryCutaneous toxicityGeneral MedicinePhlebotomymedicine.diseaseDermatologyDermatitiPolycythemia veraSettore MED/15 - Malattie Del SanguePolycythemia verahemic and lymphatic diseasesChronic Myeloproliferative NeoplasmmedicineHydroxyureaIn patientbusiness
researchProduct

Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis

2020

BACKGROUND AND OBJECTIVE MYELOFIBROSIS: is an infrequent chronic myeloproliferative neoplasm. We aimed to describe the clinico-biological characteristics, treatment, and evolutive course of myelofibrosis patients in Spain.; MATERIAL AND METHODS: A total of 1,000 patients from the Spanish Registry of Myelofibrosis diagnosed with primary (n=641) or secondary (n=359) myelofibrosis were analysed.; RESULTS: Median age was 68 years. The frequency of constitutional symptoms, moderate to severe anaemia (Hb<10g/dL), and symptomatic splenomegaly was 35%, 36%, and 17%, respectively. The rate of thrombosis and haemorrhage was 1.96 and 1.6 events per 100 patient-years, respectively. The cumulative incid…

Moderate to severePediatricsmedicine.medical_specialtyConstitutional symptomsbusiness.industrymedicine.diseaseTransplantation03 medical and health sciences0302 clinical medicineChronic Myeloproliferative NeoplasmClinical heterogeneitymedicineElderly people030212 general & internal medicineMyelofibrosisbusinessPrognostic modelsMedicina Clínica (English Edition)
researchProduct

Clinical history of thrombosis before diagnosis of overt myeloproliferative neoplasms in triple negative patients

2017

Thromboses are the most important preventable risk factors for morbidity and mortality in myeloproliferative neoplasms (MPN). We here performed a retrospective cross sectional study of patients with a diagnosis of Philadelphia negative MPN and a prior history of thrombosis, analyzed from electronic charts. Among a cohort of 260 patients with MPNs (78PV, 102ET, 80 MF), forty four were found triple negative for JAK-2, calreticulin and MPL gene mutations. Sixty-nine (26.54%) patients (29F, 40M) had a personal past clinical history of arterial or venous thrombosis. Among patients with thrombosis, 13(18.8%) cases (11ET, 2MF) were triple negative (median age:60 years). Most events, in particular …

chronic Myeloproliferative neoplasmchronic Myeloproliferative neoplasms; ThrombosisThrombosis
researchProduct